Lääkehoito aorttaläpän stenoosin ehkäisyssä Angiotensiinireseptorin salpaajan vaikutukset stenoottisen aorttaläpän tulehdukseen, fibroosiin ja kalkkiutumiseen

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2007-003162-17-FI

Enrollment

Registered

2007-06-13

Start date

2007-10-11

Completion date

Unknown

Last updated

2024-12-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aorttaläpän stenoosi MedDRA version: 9.1 Level: LLT Classification code 10002918 Term: Aortic valve stenosis

Interventions

Trade Name: Atacand Pharmaceutical Form:

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Main Objective: ;Secondary Objective: ;Primary end point(s):	—

Countries

Finland

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026